GoldenGolden
Viracta Therapeutics

Viracta Therapeutics

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

April 2017
Viracta Therapeutics raises a $18,400,000 series B round from Forward Ventures, Latterell Venture Partners, NantKwest and Wicklow Capital.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Viracta Therapeutics, Inc.
May 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that...
Viracta
May 12, 2021
www.prnewswire.com:443
/PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today...
Viracta Therapeutics, Inc.
February 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of...
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.